Testing pregnant women for HBV infection is the first step in preventing mother-to-child transmission of HBV. It identifies women who require further assessment and potential treatment and informs follow-up of exposed infants.
The indicator also provides information on HBV epidemiology among women of reproductive age.
This indicator also monitors progress towards elimination of mother-to-child transmission (EMTCT) of hepatitis B.
Definition:
Testing pregnant women for HBV infection is the first step in preventing mother-to-child transmission of HBV. It identifies women who require further assessment and potential treatment and informs follow-up of exposed infants.
The indicator also provides information on HBV epidemiology among women of reproductive age.
This indicator also monitors progress towards elimination of mother-to-child transmission (EMTCT) of hepatitis B.
(i) Percentage of pregnant women attending antenatal care (ANC) services who were tested for hepatitis B surface antigen (HBsAg) during pregnancy.
(ii) Percentage of pregnant women attending ANC services who tested positive for HBsAg among those tested.
(iii) Percentage of HBV-infected pregnant women eligible for antiviral prophylaxis according to national policy or WHO recommendations who received treatment during pregnancy.
Associated terms:
(i) HBV screening during pregnancy; antenatal HBsAg testing; PMTCT of HBV; EMTCT;
(ii) HBV prevalence in pregnancy; maternal hepatitis B infection; HBsAg positivity
(iii) HBV antiviral prophylaxis; PMTCT of HBV; maternal HBV treatment; antiviral therapy in pregnancy
Method of measurement
(i) Numerator: Number of pregnant women tested for HBsAg. Denominator: Number of pregnant women attending antenatal care services.
(ii) Numerator: Number of pregnant women with a positive HBsAg test result.
Denominator: Number of pregnant women tested for HBsAg.
(iii) Numerator: Number of eligible pregnant women who received antiviral treatment/prophylaxis for HBV.
Denominator: Number of pregnant women eligible for antiviral treatment/prophylaxis.
Method of estimation:
Routine ANC testing and programme monitoring data aggregated from facility and at national level; HBV treatment programmes and pharmacy records;National reporting systems.
Method of estimation of global and regional aggregates:
Aggregate country-reported values weighted by the number of women attending ANC when available.
Preferred data sources:
ANC registers, laboratory registers, electronic medical records, national health information systems.
Unit of Measure:
Percent (%)
Unit Multiplier:
100
Expected frequency of data dissemination:
Every two years
Expected frequency of data collection:
Continuous at country level reported every two years to WHO
Comments:
• Incomplete ANC reporting, private-sector data gaps, and variations in testing practices may affect comparability.
• Represents only women accessing ANC and tested for HBV. Availability and quality of testing may influence estimates.
• Eligibility criteria may differ across countries depending on availability of HBV DNA testing, HBeAg testing, and national treatment guidelines.
If you have any feedback, you are welcome to write it here.
If you need to access the old Global Health Observatory data, you can do it here. But before you leave, please provide us your feedback about our new data portal.
